Tepotinib Plus Cetuximab In Patients (Pts) With Ras/Braf Wild-Type Left-Sided Metastatic Colorectal Cancer (Mcrc) And Acquired Resistance To Anti-Egfr Antibody Therapy Due To Met Amplification (Metamp).

Josep Tabernero,Eric Van Cutsem,Jana Prausová,Nicolas Isambert,Cindy Neuzillet,Salvatore Siena,Filippo Pietrantonio,Stephen Falk,Zev A. Wainberg,Kanwal Pratap Singh Raghav, Nicole Campbell, Eva Liu,Regina Esser,Shaista Salim,Frank Beier,Svenja Adrian,Elena Elez,Tanios S. Bekaii-Saab

JOURNAL OF CLINICAL ONCOLOGY（2021）

引用 1|浏览3

暂无评分

摘要

TPS149Background: METamp is a secondary, or co-driving, genetic change in pts with mCRC and acquired resistance to anti-EGFR therapy, which can contribute to disease progression. In EGFR-resistant ...

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要